<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Tuesday, Feb 11th, 2020
Hilton La Jolla Torrey Pines Hotel, San Diego, CA

Interpreting the complexity of cancer with blood-based biomarkers for both tumor and immune profiling

The following topics will be discussed:

  • Why it’s important to profile both tumor & immune blood-based biomarkers
  • Tumor Profiling: data & clinical uses for cell-free ddPCR & NGS assays
  • Immune Profiling: interpreting the immune response with mass spec & NGS
  • Bringing blood-based diagnostics from discovery to the clinic

Speaker: Gary Pestano, Chief of Development at Biodesix

A seasoned biotech leader, Dr. Pestano heads up Development and Operations at Biodesix. His experience in laboratory and assay development for high complexity molecular diagnostics for oncology includes molecular and proteomic testing. Prior to joining Biodesix in 2012, Dr. Pestano led multidisciplinary teams in the development of tissue diagnostic tests, cancer vaccines and scientific software. He held senior positions in PharmaServices, R&D and Project Leadership at Ventana, a member of the Roche Group.

Dr. Pestano is the co-inventor on multiple national and international patents for diagnostic tests. He has also fostered many collaborations in academia and industry as a part of new product development. Dr. Pestano received his Ph.D. training in Cell and Molecular Biology at The Graduate Center, City University of New York and conducted his post-doctoral training in cancer immunology at the Dana Farber Cancer Institute, Harvard Medical School.